Collaboration agreement will benefit 77,000 cancer patients

Collaboration agreement will benefit to cancer patients

-The Advanced Center for Chronic Diseases, It signed a partnership with the Faculty of chemical sciences and pharmaceutical of the University of Chile and the National Cancer Corporation, Cognac.

-Red will promote research on different types of stomach tumors and also hopes to strengthen studies on gallbladder cancer prevention.

A scientific collaboration agreement, It will benefit 77,000 cancer patients in our country. This, thanks to the recent partnership signed between the Advanced Center for Chronic Diseases, ACCDiS , and the National Cancer Corporation, CONAC.

Agreement, It will promote research on different types of stomach tumors and will also seek to strengthen studies on gallbladder cancer prevention biliary (CVB), A rare and highly lethal pathology in the world.

With regard to the latter, Chile is one of the countries with the highest prevalence worldwide. The disease is the second leading cause of death in women with 90% of deaths and the fourth in men after stomach cancer, Prostate & Lung, while in other places such as the United States and Europe, the pathology has low rates of occurrence.

Gallbladder cancer

"It is necessary that research related to the prevention of this disease be carried out in our country. Therefore, This agreement boosts studies, analysis and creation of therapies in this pathology", said Dr. Sergio Lavandero, Director of the Center for advanced chronic diseases, ACCDIS.

The Dra. Catalina Agosín, President of the Cancer Corporation, Cognac, She pointed out that both for her and for the entity, The agreement is a milestone in national health, with which a new stage begins that will directly benefit 77 thousand patients who annually attend the Corporation. "In addition, Nearly 250,000 healthy asymptomatic people are regularly screened, will benefit from this agreement that unites the expertise of ACCDIS and offers new therapies and methods, to move towards controlling the disease."

Scientific work of ACCDIS

ACCDIS is a center of excellence for the study of chronic diseases formed between the University of Chile and the Pontificia Universidad Católica de Chile with the support of the FONDAP Program of CONICYT. One of the tasks of the Center is to develop research in the town of Molina, in the VII Region of Maule, listed as one of the areas with the highest number of chronic diseases in the country. "We're doing the first cohort of chronic diseases, So we have enrolled about 10 thousand healthy people, This will allow us to collect data and samples and follow the natural history of these diseases. In this way, we will be able to investigate the existence of genetic and/or environmental conditions, among other risk factors.", said Dr. Lavandero.

The study has a 10-year planning schedule and is currently in the fourth year of implementation. "The commitment of ACCDIS is to do research of the highest level, To train cutting-edge human capital and link our work with society. No doubt, this alliance will strengthen ties and benefit the patients of the National Cancer Corporation", said the director of the Center of Excellence.

A promising partnership

The Dra. Catalina Agosín, celebrates the welcome it received at the Faculty and at ACCDIS. "I found a cohesive group, motivated, not only institutionally but personally. It has been a privilege to participate with them and we believe that we must stimulate research and from the areas where we mobilize as an organization, support for this to thrive.".

However, It refers to the abysmal difference between the treatments applied in developed countries and those that are in the process of doing so. "The curves show that the effectiveness of treatments in developed countries reaches 54%. However, in adults, in our reality – and of all these nations- it barely reaches 38% to 40%".

He added that there are no limitations to moving forward quickly, "If everyone does their part, even though it's going to take many years. We can investigate, But that will depend fundamentally on the health policies in our country and the acceptance of the authority. Anyway, There has always been an excellent willingness on the part of the latter and we hope that this will be the case as well.".

Advances in early diagnosis

The Dean of the Faculty of Chemical and Pharmaceutical Sciences of the University of Chile, Arturo Squella, Particularly values the alliance, precisely because of the bond it represents with the community.

"This agreement signifies the crystallization of one of the most important reasons for our existence as a faculty. This is, that our research can reach Chileans, in this case through Conac. In this way, it is possible to contribute directly to people's well-being.", said.

The doctor highlights the work of ACCDIS and its research in favor of an early diagnosis of cancer. "I imagine that new therapies that come from these laboratories can be tested within this agreement, and in turn, scientists will be able to receive all the life experience they can get to know through Conac patients, which is going to translate into very valuable results", Arturo Squella finished. (By Gonzalo Rojas D. and María Mercedes Barraza C. Llambías Communications Agency).